GHRH and endometrium adenocarcinoma: GHRH antagonists have been implicated in the in vitro inhibition of a variety of cancer cell lines including but not limited to APL [10], AML [9], estrogen independent breast cancer [12], clear cell ovarian cancer [12], glioblastoma [12], gastric cancer [13], prostate cancer [11, 14], and endometrial adenocarcinoma [11].